OAM
NAGE

OP Asset Management’s Niagen Bioscience NAGE Stock Holding History

OP Asset Management’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-334,412
Closed -$1.47M – 840
2026
Q1 		$1.47M Buy
334,412
+306,221
+1,086% +$1.65M 0.01% 539
2025
Q4 		$179K Buy
+28,191
New +$196K ﹤0.01% 740

Other funds holding NAGE

SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
SBCM
Silverberg Bernstein Capital Management Armonk, New York $261M AUM 89.93% 1-Year Est. Return
CPIG
Chicago Partners Investment Group Chicago, Illinois $5B AUM 26.84% 1-Year Est. Return
CCIA
Campbell & Co Investment Adviser Baltimore, Maryland $1.91B AUM 17.57% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
SOADOR
State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
AWM
Axxcess Wealth Management Carlsbad, California $6.28B AUM 24.26% 1-Year Est. Return
MGI
Miller Global Investments Dallas, Texas $121M AUM
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

OP Asset Management's NAGE Position: Q2 2026 in Review

OP Asset Management sold out of Niagen Bioscience (NAGE) in Q2 2026, closing a stake of 334,412 shares — an estimated $1.47M sold.

OP Asset Management first reported a position in NAGE in Q4 2025 and held it in 2 quarters. The position peaked at $1.47M in Q1 2026. 27 funds tracked by Wall St. Rank hold NAGE as of Q2 2026.

  • OP Asset Management reported no remaining Niagen Bioscience position as of Q2 2026 after selling out during the quarter.
  • OP Asset Management sold 334,412 Niagen Bioscience shares in Q2 2026, an estimated $1.47M.
  • OP Asset Management first reported a position in Niagen Bioscience in Q4 2025 and held it in 2 quarters.
  • OP Asset Management's Niagen Bioscience position peaked at $1.47M in Q1 2026.
  • 27 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2026.

Based on OP Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.